KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Return on Equity (2017 - 2025)

Historic Return on Equity for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 0.21%.

  • Teva Pharmaceutical Industries' Return on Equity rose 3900.0% to 0.21% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.21%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 0.21% for FY2025, which is 5000.0% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Return on Equity stood at 0.21%, which was up 3900.0% from 0.09% recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Return on Equity ranged from a high of 0.21% in Q4 2025 and a low of 0.39% during Q3 2024
  • For the 5-year period, Teva Pharmaceutical Industries' Return on Equity averaged around 0.18%, with its median value being 0.22% (2023).
  • Its Return on Equity has fluctuated over the past 5 years, first tumbled by -3500bps in 2021, then soared by 4900bps in 2025.
  • Teva Pharmaceutical Industries' Return on Equity (Quarter) stood at 0.04% in 2021, then crashed by -807bps to 0.28% in 2022, then crashed by -33bps to 0.37% in 2023, then skyrocketed by 53bps to 0.17% in 2024, then surged by 223bps to 0.21% in 2025.
  • Its Return on Equity stands at 0.21% for Q4 2025, versus 0.09% for Q3 2025 and 0.03% for Q2 2025.